# Gennex Labs (NSE: GENNEX) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GENNEX · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹254 Cr, it ranks 2133rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 9.4% in FY26. In Q2 FY24, the quarter ended 30 Sep 2023, revenue was ₹20 Cr and net profit −₹1 Cr, on a consolidated basis. Promoters held 23.63% of the company as of 30 Jun 2026; 21.77% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹254 Cr |
| ROE | 9.4% (FY26) |
| ROCE | 9.9% (FY26) |
| Debt to equity | 0.16 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q2 FY24 | ₹20 Cr | — | −₹1 Cr | — | −₹0.53 |
| Q1 FY24 | ₹26 Cr | — | ₹2 Cr | — | ₹1.53 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹138 Cr | ₹18 Cr |
| FY24 | ₹87 Cr | ₹13 Cr |
| FY23 | ₹66 Cr | ₹5 Cr |
| FY22 | ₹61 Cr | ₹4 Cr |
| FY21 | ₹60 Cr | ₹4 Cr |
| FY20 | ₹56 Cr | ₹2 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 23.63%
- Domestic institutions: 0.00%
- Non-institutions: 76.37%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |
| [Everest Organic](https://app.pivotnow.in/stock/EVERESTO) | — | ₹262 Cr | — | — |
| [Kerala Ayur](https://app.pivotnow.in/stock/KERALAYUR) | — | ₹254 Cr | — | — |
| [Nath Bio-Genes (India)](https://app.pivotnow.in/stock/NATHBIOGEN) | ₹132.60 | ₹252 Cr | 6.3 | — |
| [BDH Industries](https://app.pivotnow.in/stock/BDH) | — | ₹252 Cr | — | — |

## Questions and answers

### What is the market cap of Gennex Labs?

Gennex Labs' market capitalisation is ₹254 Cr (₹254 Cr) at the 22 Oct 2026 close, ranking 2133rd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Gennex Labs?

Return on equity was 9.4% in FY26 and return on capital employed was 9.9% in FY26 (consolidated figures).

### Is Gennex Labs a debt-free company?

No. Gennex Labs' debt-to-equity ratio was 0.16 in FY26, with total debt of ₹0 Cr.

### What were Gennex Labs' latest quarterly results?

For Q2 FY24 (quarter ended 30 Sep 2023), Gennex Labs reported revenue of ₹20 Cr and net profit of −₹1 Cr.

### What is the shareholding pattern of Gennex Labs?

As of 30 Jun 2026: promoters 23.63%, domestic institutions 0.00%, non-institutions 76.37%. 21.77% of promoter shares were pledged.

### Who are Gennex Labs' competitors?

The listed Pharma & Healthcare companies closest to Gennex Labs by market cap are Espire Hospital, Zenotech Labs, Everest Organic, Kerala Ayur, Nath Bio-Genes (India) and BDH Industries.

### Is Gennex Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Gennex Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GENNEX against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.